DE60226419D1 - Somatostatin-antagonisten - Google Patents

Somatostatin-antagonisten

Info

Publication number
DE60226419D1
DE60226419D1 DE60226419T DE60226419T DE60226419D1 DE 60226419 D1 DE60226419 D1 DE 60226419D1 DE 60226419 T DE60226419 T DE 60226419T DE 60226419 T DE60226419 T DE 60226419T DE 60226419 D1 DE60226419 D1 DE 60226419D1
Authority
DE
Germany
Prior art keywords
somatostatin antagonists
somatostatin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226419T
Other languages
English (en)
Inventor
David H Coy
William A Murphy
Walajapet G Rajeswaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of DE60226419D1 publication Critical patent/DE60226419D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60226419T 2001-03-08 2002-03-05 Somatostatin-antagonisten Expired - Lifetime DE60226419D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08
PCT/US2002/006676 WO2002072602A2 (en) 2001-03-08 2002-03-05 Somatostatin antagonists

Publications (1)

Publication Number Publication Date
DE60226419D1 true DE60226419D1 (de) 2008-06-19

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226419T Expired - Lifetime DE60226419D1 (de) 2001-03-08 2002-03-05 Somatostatin-antagonisten

Country Status (16)

Country Link
US (3) US7378488B2 (de)
EP (1) EP1372688B1 (de)
JP (3) JP4204322B2 (de)
AR (1) AR035942A1 (de)
AT (1) ATE394114T1 (de)
AU (1) AU2002258465B2 (de)
CA (1) CA2439498A1 (de)
CZ (1) CZ299362B6 (de)
DE (1) DE60226419D1 (de)
DK (1) DK1372688T3 (de)
ES (1) ES2306766T3 (de)
HU (1) HUP0401535A3 (de)
NO (1) NO20033911L (de)
PL (1) PL362838A1 (de)
RU (2) RU2263678C2 (de)
WO (1) WO2002072602A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0114737A (pt) * 2000-10-20 2005-06-07 Univ Tulane Agonistas e antagonistas da urotensina-ii
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
KR20030088494A (ko) * 2001-04-09 2003-11-19 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 소마토스타틴 작용제
EP1522311A1 (de) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
WO2006063465A1 (en) * 2004-12-15 2006-06-22 Diamedica Inc. Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CN101631801B (zh) 2006-10-16 2013-06-05 索尔克生物学研究院 受体（sstr2）-选择性生长抑素拮抗剂
EP2168983A1 (de) 2008-09-30 2010-03-31 Ipsen Pharma Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
SG10201400650QA (en) 2008-10-29 2014-05-29 Kaneka Corp Method For Producing L-Amino Acid
EP2399931A1 (de) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
AU2017217271C1 (en) * 2016-02-09 2021-08-05 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE43335T1 (de) * 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
EP0278158A3 (de) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin-Inhibitoren enthaltende Phenylalanin-Histidin-Stellvertreter
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク　エンド　カムパニー　インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0273696A2 (de) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin-Inhibitoren, in denen Histidin ersetzt ist
CH679045A5 (de) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (de) 1987-08-10 1989-02-15
EP0400065B1 (de) 1988-02-10 1997-08-27 TAP Pharmaceuticals Inc. Lhrh-analog
CA2046594A1 (en) * 1989-12-08 1991-06-09 David H. Coy Octapeptide analogs of somatostatin having threonine at the sixth position
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1993003058A2 (en) 1991-07-01 1993-02-18 University Technologies International Inc. NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
KR100325972B1 (ko) * 1993-08-09 2002-07-27 바이오메져 인코퍼레이티드 치료성펩타이드유도체
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
AU728224B2 (en) 1996-12-04 2001-01-04 Administration Of The Tulane Educational Fund, The Somatostatin antagonists
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ATE430162T1 (de) * 2001-03-06 2009-05-15 Il Consorzio Ferrara Richerche Verfahren zur modulation der proliferation von schilddrüsenkrebszellen
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
KR20030088494A (ko) 2001-04-09 2003-11-19 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 소마토스타틴 작용제

Also Published As

Publication number Publication date
US20080020970A1 (en) 2008-01-24
JP2004532824A (ja) 2004-10-28
HUP0401535A3 (en) 2009-07-28
CZ299362B6 (cs) 2008-07-02
EP1372688A4 (de) 2006-06-14
WO2002072602A3 (en) 2003-03-20
NO20033911D0 (no) 2003-09-04
JP2008255120A (ja) 2008-10-23
ATE394114T1 (de) 2008-05-15
PL362838A1 (en) 2004-11-02
NO20033911L (no) 2003-10-29
CA2439498A1 (en) 2002-09-19
JP4204322B2 (ja) 2009-01-07
RU2263678C2 (ru) 2005-11-10
AU2002258465B2 (en) 2006-01-19
EP1372688B1 (de) 2008-05-07
RU2005117614A (ru) 2006-11-20
DK1372688T3 (da) 2008-08-25
US20080171853A1 (en) 2008-07-17
ES2306766T3 (es) 2008-11-16
HUP0401535A2 (hu) 2004-12-28
RU2003129807A (ru) 2005-03-20
CZ20032281A3 (cs) 2004-01-14
EP1372688A2 (de) 2004-01-02
US7408024B2 (en) 2008-08-05
JP2006342171A (ja) 2006-12-21
US7378488B2 (en) 2008-05-27
US20040181032A1 (en) 2004-09-16
RU2328504C2 (ru) 2008-07-10
AR035942A1 (es) 2004-07-28
WO2002072602A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ATE402148T1 (de) Substituierte pyridinylamine
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
NO20034497D0 (no) Somatostatin agonister
NO20014597D0 (no) Fremgangsmåte
DE60222693D1 (de) Nk1-antagonisten
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
ATE394114T1 (de) Somatostatin-antagonisten
ATE355059T1 (de) Isoxazolopyridinone
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
DE50214673D1 (de) Schnittstelle
DE50212426D1 (de) Bohrwerkzeug
DE50203093D1 (de) Losradlager
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
DE50202088D1 (de) Garmodulsystem
ATA13992002A (de) Schlackengranulierungsanlage
DE10295006D2 (de) Bauwerksabdichtung
DE60216967D1 (de) Substituierte cyclohexanderivate
ATE405973T1 (de) Steckverbindung
ATA2892002A (de) Beschlag
AT500276B8 (de) Radschwenksystem
ATE345337T1 (de) Delta1 -pyrroline

Legal Events

Date Code Title Description
8364 No opposition during term of opposition